Tidal Investments LLC Increases Stock Position in Boston Scientific Corporation $BSX

Key Points

• Tidal Investments increased its Boston Scientific position by 29.2% in the second quarter, adding 66,582 shares for a total of 294,851 shares valued at approximately $12.6 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific exceeded quarterly expectations, reporting $0.86 in EPS and $5.44 billion in revenue, with revenue up 7.5% year over year. The company also authorized a $5 billion share-repurchase program covering up to 6.4% of outstanding shares.
• Insiders bought roughly $9.4 million of stock over the past 90 days, including a major purchase by CEO Michael Mahoney. Analysts maintain a “Moderate Buy” consensus with an average price target of $71.46, despite shares trading near $43.

Tidal Investments LLC boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 29.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 294,851 shares of the medical equipment provider's stock after acquiring an additional 66,582 shares during the quarter. Tidal Investments LLC's holdings in Boston Scientific were worth $12,584,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. FWL Investment Management LLC purchased a new position in shares of Boston Scientific in the second quarter worth $26,000. Swiss RE Ltd. bought a new position in shares of Boston Scientific during the fourth quarter valued at $26,000. Garton & Associates Financial Advisors LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $26,000. Sfam LLC purchased a new stake in shares of Boston Scientific during the fourth quarter valued at $29,000. Finally, South Plains Financial Inc. bought a new stake in Boston Scientific in the 4th quarter worth about $39,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Trading Down 0.2%

Shares of NYSE:BSX opened at $43.00 on Friday. The stock's 50-day simple moving average is $47.00 and its two-hundred day simple moving average is $54.66. The stock has a market capitalization of $62.31 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 1.00 and a beta of 0.57. Boston Scientific Corporation has a 52-week low of $42.20 and a 52-week high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business's revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Analysts expect that Boston Scientific Corporation will post 3.29 EPS for the current year.

Boston Scientific announced that its Board of Directors has approved a share repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's leadership believes its stock is undervalued.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney acquired 186,240 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the transaction, the chief executive officer directly owned 1,590,024 shares in the company, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David C. Habiger acquired 2,100 shares of Boston Scientific stock in a transaction dated Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at $816,644.40. This represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders acquired 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. The Goldman Sachs Group set a $71.00 target price on shares of Boston Scientific in a research note on Thursday, May 28th. Oppenheimer decreased their price objective on shares of Boston Scientific from $90.00 to $85.00 and set an "outperform" rating for the company in a report on Monday, July 27th. Raymond James Financial restated an "outperform" rating and set a $57.00 price objective on shares of Boston Scientific in a research report on Thursday, July 30th. Zacks Research cut shares of Boston Scientific from a "hold" rating to a "strong sell" rating in a report on Friday, June 5th. Finally, Needham & Company LLC cut their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday, July 8th. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $71.46.

About Boston Scientific

Boston Scientific Corporation is a medical device company that develops, manufactures and markets products used in minimally invasive procedures. Its technologies are designed to diagnose and treat a range of medical conditions while supporting less invasive alternatives to traditional surgery.

The company's products address cardiovascular, endoscopy, urology, pelvic health and neuromodulation applications. Its portfolio includes devices used in cardiac rhythm management and electrophysiology, structural heart procedures, peripheral and vascular interventions, gastrointestinal procedures, kidney stone and prostate treatments, and therapies for chronic pain and other neurological conditions.

Founded in 1979, Boston Scientific serves healthcare providers and patients in markets around the world.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.